Showing 1661-1670 of 5771 results for "".
- OcuTerra Therapeutics Announces First Patient Dosed in OTT166 Phase 2 DR:EAM Clinical Trial for Diabetic Retinopathyhttps://modernod.com/news/ocuterra-therapeutics-announces-first-patient-dosed-in-ott166-phase-2-dream-clinical-trial-for-diabetic-retinopathy/2481009/OcuTerra Therapeutics announced that the first patient was dosed in its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating OTT166 in adult patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) or mild proli
- Aerie Pharmaceuticals Announces First Patient Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-announces-first-participant-dosed-in-the-comet-3-study-of-ar-15512-for-the-treatment-of-dry-eye-disease/2481006/Aerie Pharmaceuticals announced that the first participant has been dosed in the phase 3 registrational “COMET-3” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-3 is the second of three trials in the p
- EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-phase-2-davio-2-clinical-trial-of-eyp-1901-for-the-maintenance-treatment-of-wet-amd/2481005/EyePoint Pharmaceuticals, Inc., announced that the first patient has been dosed in the Phase 2 Durasert® and Vorolanib in Ophthalmology 2 (DAVIO 2) clinical trial of EYP-1901, an investigational sustained delivery antivascular endothelial growth factor (anti-VEGF) treatment for wet
- Yuyu Pharma Announces First Patient Enrolled in Phase 2 Study of YP-P10 Ophthalmic Solution for the Treatment of Dry Eye Diseasehttps://modernod.com/news/yuyu-pharma-announces-first-patient-enrolled-in-phase-2-clinical-study-evaluating-yp-p10-ophthalmic-solution-for-the-treatment-of-dry-eye-disease/2480996/Yuyu Pharma announced the enrollment of the first patient in a phase 2 clinical study evaluating YP-P10, a novel and patented synthetic peptide with anti-inflammatory and wound healing properties being investigated to treat patients with dry eye disease (DED). Yuyu received cl
- Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Trianglehttps://modernod.com/news/atsena-therapeutics-announces-opening-of-new-office-and-laboratory-space-in-north-carolinas-research-triangle/2480994/Atsena Therapeutics announced the opening of its new office and laboratory in the Alexandria Center for Advanced Technologies–Research Triangle. The occasion was celebrated during a ribbon-cutting ceremony yesterday. The new state-of-the-art facility consist
- Pixium Vision Announces Successful Implantation of First Patient in the Netherlands in Prima System European Pivotal Trial PRIMAverahttps://modernod.com/news/pixium-vision-announces-successful-implantation-of-first-patient-in-the-netherlands-in-prima-system-european-pivotal-trial-primavera/2480993/Pixium Vision announced the successful implantation of the first patient in the Netherlands in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (AMD). This follows approval of the PRIMAvera study by the Dutch Ministry of Health, Welfare and Sport and the open
- RD Fund Announces New Chair and Expansion of Board of Directorshttps://modernod.com/news/rd-fund-announces-new-chair-and-expansion-of-board-of-directors/2480990/The RD Fund (Retinal Degeneration Fund)—the venture arm of the Foundation Fighting Blindness aimed at driving research toward preventions, treatments, and cures for the entire spectrum of retinal degenerative diseases—announced the appointment of Adrienne Graves, P
- Nanoscope Therapeutics Announces First Patient Dosed in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Diseasehttps://modernod.com/news/nanoscope-therapeutics-announces-first-patient-dosed-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease/2480985/Nanoscope Therapeutics announced that the first patient has been dosed in a phase 2 trial of its Multi-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic monotherapy for Stargardt disease. “This trial represents the second indication for our vision restoring
- Carl Zeiss Meditec and Precise Bio Announce Partnership in the Development and Commercialization of Tissue-Based Implants for Ophthalmologyhttps://modernod.com/news/carl-zeiss-meditec-and-precise-bio-announce-partnership-in-the-development-and-commercialization-of-tissue-based-implants-for-ophthalmology/2480984/Carl Zeiss Meditec and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, announced that the companies have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial ke
- Second Sight Medical Products Announces Year 4 NIH Funding of its Orion Studyhttps://modernod.com/news/second-sight-medical-products-announces-year-4-nih-funding-of-its-orion-study/2480982/Second Sight Medical Products announced that the company received notice from the National Institutes of Health (NIH) of the release of year 4 funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (Orion Trial), grant 5UH3NS103442. The NIH released&n